Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is characterized by a complex genomic landscape, with both genetic and epigenetic diversity contributing to its pathogenesis, disease course, and response to treatment. To better understand the association between genomic features and response to treatment am...
Main Authors: | Russell Keathley, Masha Kocherginsky, Ramana Davuluri, Daniela Matei |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/14/3649 |
Similar Items
-
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01) -
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
by: Lu Zhang, et al.
Published: (2021-11-01) -
Cell Origins of High-Grade Serous Ovarian Cancer
by: Jaeyeon Kim, et al.
Published: (2018-11-01) -
Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
by: Marcus Vetter, et al.
Published: (2022-11-01) -
Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer
by: Monika Raab, et al.
Published: (2024-01-01)